C12N 2770/32033
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/32033 (Use of viral protein as therapeutic agent other than vaccine) appears on 9 US grants and 13 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 13
- Assignees
- 7
- Inventors
- 33
- Latest grant
- 18 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 1 | 2 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 0 |
| 2019 | 0 | 1 |
| 2020 | 1 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 2 |
| 2023 | 1 | 0 |
| 2024 | 0 | 3 |
| 2025 | 1 | 0 |
By publication year.
Recent patents
- Seneca valley virus (SVV) cellular receptor targeted oncotherapy18 Nov 2025US 12,472,218 B2Memorial Sloan Kettering Cancer Center
- Seneca valley virus (SVV) cellular receptor targeted oncotherapy29 Aug 2023US 11,738,058 B2Memorial Sloan Kettering Cancer Center
- Seneca Valley Virus (SVV) cellular receptor targeted oncotherapy24 Aug 2021US 11,096,972 B2Memorial Sloan Kettering Cancer Center
- Seneca valley virus (SVV) cellular receptor targeted oncotherapy21 Jan 2020US 10,537,599 B2Memorial Sloan Kettering Cancer Center
- Methods and materials for reducing the severity of viral infections29 May 2018US 9,981,019 B2Mayo Foundation for Medical Education and Research
- Compounds, compositions, and methods of using thereof7 Nov 2024US 2024/0366518 A1ElevateBio Technologies, Inc.
- Compounds, compositions, and methods of using thereof30 May 2024US 2024/0173267 A1Oncorus, Inc.
- Seneca valley virus (svv) cellular receptor targeted oncotherapy2 May 2024US 2024/0139267 A1Memorial Sloan Kettering Cancer Center
- Genetically Engineered Cells and Uses Thereof16 Jun 2022US 2022/0184123 A1Century Therapeutics, Inc.
- Seneca valley virus (svv) cellular receptor targeted oncotherapy24 Feb 2022US 2022/0054564 A1Memorial Sloan Kettering Cancer Center
Most cited
By later US patents
- Seneca Valley virus based compositions and methods for treating disease5US 7,638,318 B2Norvartis AG · 2009
- Seneca Valley virus based compositions and methods for treating disease4US 8,039,606 B2Novartis AG · 2011
- Seneca valley virus (SVV) cellular receptor targeted oncotherapy3US 10,537,599 B2Memorial Sloan Kettering Cancer Center · 2020
- Seneca Valley Virus (SVV) cellular receptor targeted oncotherapy3US 11,096,972 B2Memorial Sloan Kettering Cancer Center · 2021
- Seneca valley virus based compositions and methods for treating disease3US 8,753,622 B2Novartis AG · 2014